Novartis finalizes seventh new US facility in $23 billion expansion
Novartis finalized a seventh new US facility as part of a $23 billion expansion. The new API site in Morrisville, North Carolina, supports end-to-end US manufacturing across multiple therapy platforms.
Novartis has finalized plans for a seventh new facility as part of a $23 billion investment aimed at reshaping how it develops and delivers medicines in the United States. The latest addition is a new active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, which will produce key components for solid dosage tablets, capsules, and RNA therapeutics.
Once operational, the Morrisville site will complete a critical missing link in the company’s US footprint: end-to-end manufacturing, from raw active ingredients to finished medicines, entirely on American soil. The 56,200-square-foot site expands its North Carolina presence to five facilities across three locations.
The milestone marks the seventh facility confirmed within a year of the company’s initial US investment announcement. The company said it has made rapid progress since April 2025 on its goal to manufacture all key medicines for US patients within the country, particularly high-demand and time-sensitive treatments such as radioligand therapies.
The expansion has accelerated across multiple states:
- In February 2026, the company broke ground on a biomedical research center in San Diego, California, expanding its US research network alongside Cambridge, Massachusetts, and strengthening work in neuroscience and oncology.
- In February 2026, it announced a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, extending its cancer treatment production network to five sites.
- In January 2026, it unveiled another RLT facility in Winter Park, Florida, the first of its kind in the Southeastern US.
- In December 2025, the company began construction on a major North Carolina manufacturing hub for tablets, capsules, biologics, and packaging across multiple therapeutic areas.
- In November 2025, it opened a California RLT facility in Carlsbad, serving patients across the Western US, Alaska, and Hawaii.
- Expansions continue at existing RLT sites in Indianapolis, Indiana, and Millburn, New Jersey.
Taken together, the buildout is steering the company toward a fully integrated US manufacturing system covering small molecules, biologics, RNA-based therapies, cell and gene therapies, and radioligand treatments. The company said it is on track to achieve end-to-end US production across all advanced technology platforms.